KDR and neoplasm: Anti-VEGF-A refractory tumors enhanced galectin-1 secretion together with its increased binding to neovascular endothelial cells due to altered glycosylation patterns on VEGFR2, leading to galectin-1-driven angiogenesis and tumor progression [63].